Tooth-regrowth research has reached human drug development, but that is not the same as a treatment that replaces any missing adult tooth. The most concrete development in the sources checked for this guide is TRG035, an investigational antibody program initially targeting congenital tooth agenesis—teeth that did not develop. Its developer announced a Japanese Phase IIa trial-notification milestone in August 2026. That announcement did not report successful tooth growth in the trial. 1
The distinction between a tooth that never formed, a tooth lost after it formed, and damage to a tooth still in the mouth explains much of the confusion surrounding the phrase “regrowing teeth.” They are not interchangeable research problems.
The three different things called tooth regrowth
| What a reader may mean | What the process actually involves | Where to find the relevant evidence |
|---|---|---|
| Repair an early damaged tooth surface | Restore minerals to enamel that has begun to demineralize | Enamel repair versus regrowth |
| Develop an additional natural tooth | Investigate a developmental pathway, including anti-USAG-1 research | How the USAG-1 approach works |
| Replace an absent tooth for chewing | Use a replacement such as an implant-supported restoration | Regrowth versus implants |
Early mineral loss can be reversible; an established cavity represents permanent damage requiring repair. Neither process means a completely absent tooth has regenerated. An implant, meanwhile, is an artificial replacement system rather than a newly developed tooth. 2 3
What changed in 2026?
The August announcement concerns the development status of a particular drug candidate, not the commercial launch of a dental procedure. The TRG035 report separates the earlier first-in-human plan from the subsequent Phase IIa notification and explains exactly what the current source does—and does not—establish. 1 4
This is an important difference in a field where a single headline can make three separate promises seem identical: “researchers have a mechanism,” “researchers are testing a drug,” and “dentists can now offer new teeth.” Each requires different evidence. The available announcement supports the middle proposition, not the last one.
Who is the initial target population?
Toregem describes an initial focus on congenital tooth agenesis and a longer-term ambition to address acquired tooth loss. The latter is an expansion goal. It is not an outcome established by the congenital program. 5
For someone who lost an adult molar, the unanswered issue is therefore not just how quickly a drug might be approved. It is whether that person's type of tooth loss is covered by the research in the first place. A successful result in one developmental condition would still need an evidence bridge before being generalized to another.
This also explains why the presence of adults in an early safety study does not automatically identify the eventual treatment population. Safety experiments and efficacy experiments can ask different questions in different participants. The historical Kitano Hospital plan should not be repurposed as a current consumer enrollment advertisement. 4
Is there a confirmed release date or price?
The cited trial milestone does not establish a public release date, approved patient price or routine dental availability. A proposed future year is not equivalent to a regulator's marketing authorization. A price for a different dental procedure is not a price for TRG035. 1
A credible availability claim would identify the authorized product, country, indication and route through which eligible people can actually receive it. A registration page, a reservation request or a clinic's general discussion of regeneration cannot substitute for those facts.
We have not turned an unverified launch estimate into a countdown. That means the page can answer the availability question directly without pretending that the answer is more definite than the evidence allows.
What would make the next result clinically persuasive?
For this publication, an informative human tooth-regrowth result would describe more than a promising image. Our assessment would distinguish whether a tooth developed, where it developed, what tissues were present, whether it erupted, whether it was useful for biting and how long observation continued. Safety would include unwanted effects as well as whether the desired tooth appeared.
Those are proposed evaluation criteria, not a claim that the present trial has already supplied every measurement. They make the hoped-for benefit explicit. A biological signal, a radiographic finding and a durable functional tooth are different claims even when they belong to the same research program.
How this guide fits together
The program report answers what happened in the trial pathway. The mechanism explainer answers why USAG-1 is being targeted. The comparisons answer why enamel products and established replacement procedures should not be confused with the drug.
This is a selected evidence guide, researched through September 17, 2026—not a census of every laboratory working on dental regeneration. It covers the claims its linked documents can support and preserves the distinction between demonstrated results and development plans.